medtech-diagnostics theme · 37 dossiers

Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating…

Life-settlements franchise attached itself to the RWA-tokenization narrative on 2026-07-07 (100+ policies on-chain, targeting the $224B secondary market by year-end); Q1 beat and raised FY adj-EPS guide to $1.00–1.05. But price rejected…

All-cash $25.00 take-private of Avanos by American Industrial Partners is now a near-closed pin: all regulatory approvals obtained 2026-07-02, leaving only the 2026-07-22 shareholder vote before an expected close by 2026-07-27. The spread…

TAVR disruptor whose de-risking catalysts (CMS CED 4/28, first US patients 5/5, French ANSM clearance 6/8) are now exhausted; price ran to a fresh ~$11.06 high then faded to $9.77 (7/10) on no news, back near the in-the-money $250M ATM…

Value-unlock special situation, not momentum: ~$10.90/share net cash, Politan Capital (~10%) on the board, and a portfolio review under a new multiomics chief. The ~+60% bounce off the $15.93 low has run ahead of still-contracting organic…

Broken-growth AID-pump name in a pre-earnings holding pattern: the ~2026-07-28 Q2 print is the binary that decides whether new patient starts re-accelerate or post a second straight sequential decline. June's ~$14 relief bounce off the…

Post-ASMS product-cycle re-rate has matured into a based-out momentum leg: the low-$40s→$64.54 June run held near $55, and the sell-side kept chasing Guggenheim $53→$70 (2026-06-29), Leerink Outperform $70 (2026-07-07), Citi Neutral $60…

Analyst-confirmed profitability inflection (Q1'26: adj-EBITDA +$4.0M, +$6.2M op cash, +24% product rev) in a 25-year blood-safety grinder but the 2.7x off the lows is largely spent and price is pinned at 52-week highs (~$3.19 vs $3.21).…

CNS gene-therapy delivery arms-dealer for uniQure's AMT-130 (Huntington's BLA planned Q3 2026). The June re-rate held near $18.72 rather than reverting, but the near-term binary is spent and the theme has cooled to maturing no dated…

Premium-golf consumable franchise (Titleist Pro V1) catching a defensive-quality rotation bid; JPM's 2026-06-26 Positive Catalyst Watch (PT $96→$118, Q2 growth 11.8% vs 10.3% cons) frames the ~2026-08-06 Q2 print as the confirmation. But…

Plasma/IVIG re-rating has stalled just under YTD highs (~$76) as sell-side finishes flipping from cuts to raises now the base case rather than an edge. Citi's July 8 "downside 90-day catalyst watch" (PT $79, Neutral) frames the Aug 6 Q1…

Med-device turnaround re-rating is now fully banked into Hold-grade targets: BMO initiated Market Perform $19 (Jul 9) and Citi raised to Neutral $19 (Jul 8), both landing on the tape (~$18.76). The distressed-to-fair leg is done; only…

Analyst-momentum re-rating on a beaten-down CRO: Q1 2026 beat (adj EPS $2.50 vs $2.42) plus two upgrades in a week RBC Outperform $185 (06-25) and Truist Buy $207 (06-30) but price still trades below its 200-EMA and the Q1 catalyst has…

Medtronic diabetes spinoff's momentum has fully faded: MMED closed $15.59 (2026-07-02), ~22% below its $20 March IPO and under every analyst target but the $16 low, after the June 3 print-plus-Abbott spike round-tripped. Q4 organic growth…

Post-COVID survivor re-rate has gone parabolic: +31% in three weeks to a fresh 52-week high of $6.22 (June 26), clearing every analyst target on the May 7 Q1 beat-raise, June 2 refi and June 15 TriLink GMP enzyme facility. The move is…

Legacy hereditary-cancer testing house pivoting into the crowded ctDNA/MRD market; June 23 Precise MRD expansion + MONITOR-Breast publication sparked a +9.2% bounce off 52-week lows, but core revenue grows ~2% with negative EBITDA a…

Sell-side discovery leg has played out fast from one Canaccord Buy ($32, 2026-06-04) to a 3-broker Strong Buy cluster (Mizuho/Oppenheimer $30) plus S&P Healthcare Equipment index inclusion (2026-06-12), driving fresh highs near $30. Price…

Divestiture rumor (~$1.5B POC-unit sale) off the 52w low, theme MATURING; binary on deal close, not narrative-momentum track a signed deal.

Only year-long implantable CGM, clinically de-risked at ADA 2026 with fundamentals accelerating (rev +72% YoY TTM), yet the stock printed a fresh 52-week low at $4.79 AFTER its biggest catalyst of the year accelerating story, dead tape,…

SI-joint-fusion grower adding a Smith+Nephew pelvic-trauma distribution leg; tape has firmed from broken to basing and is now testing the ~$17 200-day resistance shelf. Still a mid-teens grower (+11.2% Q1), not hypergrowth the ~2026-08-03…

Post-Alcon-break special situation where the June 18 standstill expiry + annual meeting passed with no renewed sale process Broadwood slate re-elected, equity plan boosted, nothing on a sale. The near-term M&A binary deflated. Residual…

Now a merger-arb special situation: Merck KGaA's $73/share all-cash takeout (announced 2026-06-25, $11.3B EV) caps upside at the bid and extinguished the chart. Analyst targets collapsed to $73 the next day; what remains is thin…

Beaten-down insulin-pump turnaround where the entire re-rate hinges on the tubeless Mobi 510(k) targeted for Q2 2026 submission, now overdue for confirmation plus gross margin scaling toward ~60% by Q4. But price is rolled over near the…

Synthetic-DNA re-accelerating on a Barclays $95 cluster but the $70-pivot breakout failed once, CEO sold $3.2M and a mixed-shelf overhangs watch the $70 — reclaim.

Busted-growth genomics name recovering off the −49% May guide-cut crash ($170→$32); sell-side ratcheting targets back up (Guggenheim $74 Jun 29, Piper $63 Jun 23), but the ~early-Aug Q2 ARR print vs the ~$3,300 baseline is the binary. A…